Q2 FY2026 EarningsQ2 FY26 beat consensus across top and bottom lines: revenue $109.4M vs. $109.1M expected, and GAAP EPS of $0.15 vs. $0.19 expected mean (though beating the low-end). Oncology revenue surged 176% YoY, and gross margin improved to 70.0%. Management reiterated FY26 revenue guidance of $450M-$465M, in-line with the consensus mid-point, while achieving a significant swing to positive operating income of $5.5M.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Billiontoone(BLLN) the Revenue is 109.45 M (--%), Beat estimate;the EBIT is 5.503 M (--%), Miss estimate;the EPS is 0.15 (--%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.11B--
0.11B--
+0.00B--%
EBITMiss expectations
0.01B--
0.01B--
-0.00B--%
EPSMiss expectations
0.15--
0.1885--
-0.0385--%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf